Alnylam Pharmaceuticals (ALNY) Stock Price vs Diluted EPS
Open the interactive overlay on autario.com.
Alnylam Pharmaceuticals' Diluted EPS improved significantly year-over-year in Q3, rising from -0.87 USD/share in Q3 2024 to 1.84 USD/share in Q3 2025, marking the company's return to profitability on a per-share basis. Over the same one-year period, the stock price increased from approximately 194.46 USD (August 2023) to 285.38 USD (June 2026), representing a 47% gain. The stock's appreciation outpaced the EPS swing from negative to positive territory, indicating investors expanded their valuation multiple as the company approached sustained profitability. Across the broader 22-year window from June 2004 to June 2026, the stock rose from 7.00 USD to 285.38 USD while the company remained unprofitable on a diluted EPS basis through most periods, with a 0.64 correlation between stock price and quarterly diluted EPS reflecting the market's focus on long-term revenue growth and pipeline potential rather than near-term earnings.
Diluted EPS was $1.84/share as of 2025-09-30 (10-Q); the stock traded at $456.00. Not enough overlapping price and reporting history yet for a year-over-year comparison.
Latest close: 287.77 USD (2026-06-02).
Diluted EPS | recent SEC reports
| Report date | Diluted EPS | Period |
|---|
| 2025-09-30 | 1.84 USD/share | Q3 10-Q |
| 2025-06-30 | -0.51 USD/share | Q2 10-Q |
| 2024-09-30 | -0.87 USD/share | Q3 10-Q |
| 2024-06-30 | -0.13 USD/share | Q2 10-Q |
| 2024-03-31 | -0.52 USD/share | Q1 10-Q |
| 2023-09-30 | 1.15 USD/share | Q3 10-Q |
| 2023-06-30 | -2.21 USD/share | Q2 10-Q |
| 2023-03-31 | -1.40 USD/share | Q1 10-Q |
Sources: autario.com/data/stock-alny-alnylam-pharmaceuticals-daily-prices · autario.com/data/alnylam-pharmaceuticals-diluted-eps-sec-filings | data verified and hosted on autario.com.